Eli Lilly and Co
(MIL:1LLY)
€
733.1
-11.4 (-1.53%)
Market Cap: 703.72 Bil
Enterprise Value: 729.10 Bil
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 66/100 
Eli Lilly and Co at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 24, 2021 / 06:40PM GMT
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst
Good afternoon. Welcome, everybody, to the afternoon session of our global healthcare conference this year. I'm delighted to welcome Lilly to our presentation and virtual -- on a virtual basis. Lilly is represented by Ilya Yuffa, who's President of Lilly Bio-Medicines, And Ilya is responsible for all the Phase III immunology, pain and related programs as well as for the commercial responsibility for this very broad portfolio. So Ilya, thank you for joining us today.
Ilya Yuffa
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines
Great to be here with you, Geoff. Thank you very much.
Questions & Answers
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst
So this is a pretty big portfolio, and there's a lot going on. Obviously, your COVID
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers